Skip to main content
SpringerLink
Log in

LH-RH Agonists in the Treatment of Premenopausal Patients with Advanced Breast Cancer

  • Chapter
Peptides in Oncology I

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 124))

Abstract

Ovarian ablation has a long-standing history in the treatment of metastatic breast cancer. At the end of the last century, Schinzinger [34] and Beatson [1] independently reported on the beneficial effect of surgical removal of the ovaries in premenopausal women with advanced breast cancer. Subsequently, this treatment became the standard systemic hormonal therapy in such patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Beatson GT (1896) On the treatment in operablic cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases Lancet 2:104–107, 162-165

    Article  Google Scholar 

  2. Buchanan RB, Blarney RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG (1986) A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol 4:1326–1330

    PubMed  CAS  Google Scholar 

  3. Conte CC, Nemoto T, Rosner D, Dao TL (1989) Therapeutic oophorectomy in metastatic breast cancer. Cancer 64:150–153

    Article  PubMed  CAS  Google Scholar 

  4. Eidne KA, Flanagan CA, Harris NS, Millar RP (1987) Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab 64:425–32

    Article  PubMed  CAS  Google Scholar 

  5. Foekens JA, Henkelman MS, Bolt-deVries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LHRH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factor, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18:369–380

    Google Scholar 

  6. Foekens JA, Henkelman MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer 22:(Abstr III-s), 725

    Google Scholar 

  7. Hardt W, Schmidt GM (1983) Sustained gonadal suppression in fertile women with the LHRH agonist buserelin. Clin Endocrinol Oxf 19:613–7

    Article  PubMed  CAS  Google Scholar 

  8. Harvey HA, Lipton A, Max DT, Pearlman OHG, Diaz-Perches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog Leuprolide in metastatic breast cancer. Proc Amer Soc Clin Oncol 3:(Abstr C-435), 111

    Google Scholar 

  9. Harvey HA, Lipton A, Max DT, Perlman OHG, Diaz-Perches R, de la Garza J (1985) Medical castration produced by the GnRH analog leuprolide to treat metastatic breast cancer. J Clin Oncol 3:1086–1072

    Google Scholar 

  10. Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glode LM, Sealoff A, Landau RL, Schneir H, Max DT (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Assoc Cancer Res & Amer Soc Clin Oncol 22:(Abstr C-436), 444

    Google Scholar 

  11. Hayward HA, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13:89–94

    Google Scholar 

  12. Henderson IC, Cannelos GP (1980) Cancer of the breast: the past decade. N Engl J Med 302:17–30, 78-90

    Article  PubMed  CAS  Google Scholar 

  13. Höffken K (1988) LH-RH agonists in oncology. Springer, Berlin Heidelberg New York

    Book  Google Scholar 

  14. Höffken K, Oesterdickhoff C, Becher R, Callies R, Kurschel E, Anders CU, Scheulen ME, Schmidt CG (1989) LH-RH agonist treatment with buserelin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Ther Control 1:13–20

    Google Scholar 

  15. Hoogstraten B, Fletcher WS, Gad-el-Mawla N, Maloney TR, Altman SJ, Vaughn CB, Foulkes MA (1982) Tamoxifen and oophorectomy in the treatment of recurrent breast cancer. A southwest oncology group study. Cancer Res 42:4788–4791

    PubMed  CAS  Google Scholar 

  16. Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54:2248–2256

    Article  PubMed  CAS  Google Scholar 

  17. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM (1986) Randomized trial of bilateral oophrec-tomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4:178–185

    PubMed  CAS  Google Scholar 

  18. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Jänicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H, Strunz P, Schachner-Wünschmann E, Bastert G, Maass H (1989) Goserelin, a depot gonadotropin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 7:1113–1119

    PubMed  CAS  Google Scholar 

  19. Klijn JGM (1984) Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments. Med Oncol Tumor Pharmacother 1:123–8

    PubMed  CAS  Google Scholar 

  20. Klijn JGM, de Jong FH (1982) Treatment with a luteinizing hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1:1213–1216

    Article  PubMed  CAS  Google Scholar 

  21. Klijn JGM, de Jong FH (1987) Long-term LHRH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18:343–352

    Google Scholar 

  22. Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23:867–873

    Article  PubMed  CAS  Google Scholar 

  23. Klijn JGM, Paridaens R, Foekens JA (1987) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Monograph Series of the European Organization for Research on Treatment of Cancer (EORTC) 18

    Google Scholar 

  24. Legha SS, Davis HL, Muggia FM (1978) Hormonal therapy of breast cancer: new approaches and concepts. Ann Intern Med 88:69–77

    PubMed  CAS  Google Scholar 

  25. Manni A, Pearson OH (1976) Antiestrogen-induced remissions in stage IV breast cancer. Cancer Treat Rep 60:1445–1450

    PubMed  CAS  Google Scholar 

  26. Manni A, Pearson OH (1980) Antiestrogen-induced remission in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64:779–785

    PubMed  CAS  Google Scholar 

  27. Nicholson RI, Maynard PV (1979) Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39:268–273

    Article  PubMed  CAS  Google Scholar 

  28. Planting AST, Alexieva-Figusch J, Blonk-vdWist J, van Putten WLJ (1985) Tamoxifen therapy in premenopausal women with metastatic breast cancer. Cancer Treat Rep 69:363–368

    PubMed  CAS  Google Scholar 

  29. Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in postmenopausal women with luteinizing hormone releasing hormone (ICI 118630) therapy. Eur J Cancer 22:746 (Abstract 111-18)

    Google Scholar 

  30. Pritchard KI, Thomson DB, Myers RE, Sutherland D, Mobb BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64:787–796

    PubMed  CAS  Google Scholar 

  31. Sandow J, Fraser HM, Seidel H, Krauss B, Jarabek-Sandow G, Von Rechenberg W (1987) Buserelin: pharmacokinetics, metabolism and mechanisms of action. Br J Clin Pract 41:6–13

    Google Scholar 

  32. Schacter LP, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L (1990) Overview of hormonal therapy in advanced breast cancer. Semin Oncol 17:38–46

    PubMed  CAS  Google Scholar 

  33. Schally AV, Redding TW, Comaru SA (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68:281–289

    PubMed  CAS  Google Scholar 

  34. Schinzinger AS (1889) Über Carcinoma mammae. Zbl Chir (Beil) 16:55–56

    Google Scholar 

  35. Waxman JH, Harland SJ, Coombes RC, Wrigley P, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol 15:171–173

    Article  PubMed  CAS  Google Scholar 

  36. Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53:629–636

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, W-4300, Essen, FRG

    K. Höffken

Authors
  1. K. Höffken
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, W-4300, Essen, Germany

    K. Höffken

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Höffken, K. (1992). LH-RH Agonists in the Treatment of Premenopausal Patients with Advanced Breast Cancer. In: Höffken, K. (eds) Peptides in Oncology I. Recent Results in Cancer Research, vol 124. Springer, Milano. https://doi.org/10.1007/978-88-470-2186-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2186-0_9

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-2188-4

  • Online ISBN: 978-88-470-2186-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation